Get the Stockscreener App
7.24
7.42%
-0.58
Pre-market:
7.60
0.36
+4.97%
Allurion Technologies Inc stock is traded at $7.24, with a volume of 74,781.
It is down -7.42% in the last 24 hours and down -23.18% over the past month.
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
See More
Previous Close:
$7.82
Open:
$7.71
24h Volume:
74,781
Relative Volume:
3.14
Market Cap:
$19.63M
Revenue:
$64.42M
Net Income/Loss:
$-73.78M
P/E Ratio:
-4.2386
EPS:
-1.7081
Net Cash Flow:
$-60.50M
1W Performance:
-30.58%
1M Performance:
-23.18%
6M Performance:
-72.42%
1Y Performance:
-91.51%
1-Day Range:
$7.05
$8.1799
1-Week Range:
$7.05
$10.90
52-Week Range:
$6.50
$98.75
Allurion Technologies Inc Stock (ALUR) Company Profile
Name
Allurion Technologies Inc
Sector
Industry
Phone
508-647-4000
Address
11 HURON DR STE 200, NATICK
Compare ALUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALUR
Allurion Technologies Inc
|
7.24 | 19.63M | 64.42M | -73.78M | -60.50M | -1.7081 |
|
ABT
Abbott Laboratories
|
114.25 | 198.16B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.95 | 141.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
364.10 | 138.80B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
82.68 | 106.02B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.15 | 43.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Allurion Technologies Inc Stock (ALUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-02-24 | Initiated | TD Cowen | Buy |
| Sep-06-24 | Initiated | ROTH MKM | Buy |
| Feb-09-24 | Initiated | Jefferies | Buy |
Allurion Technologies Inc Stock (ALUR) Latest News
Allurion reports promising results from obesity treatment trial By Investing.com - Investing.com Canada
Allurion Announces Positive Topline Results From AUDACITY Trial - BioSpace
Allurion Technologies Enhances Financial Agreements and Governance - TipRanks
Allurion announces AUDACITY trial meets one co-primary endpoint, misses other - TipRanks
Allurion reports promising results from obesity treatment trial - Investing.com India
Allurion Technologies expands board, appoints new director - Investing.com
Allurion Technologies expands board, appoints new director By Investing.com - Investing.com Canada
Allurion Technologies Expands Board with New Appointment - MSN
Allurion Technologies, Inc. (ALUR) Loses -38.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Allurion Technologies Inc. Withdraws the Device from the French Market - Marketscreener.com
Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss - Marketscreener.com
Allurion Technologies, Inc. Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s - Marketscreener.com
Allurion Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Allurion Technologies, Inc. Announces an Expanded Commercial Agreement with Weight Doctors - Marketscreener.com
Certain Restricted stock units of Allurion Technologies Inc. are subject to a Lock-Up Agreement Ending on 27-SEP-2024. - Marketscreener.com
Allurion Technologies Inc. Announces Chief Financial Officer Changes - Marketscreener.com
Allurion Technologies, Inc. Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity - Marketscreener.com
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance - Marketscreener.com
Allurion Receives Continued Listing Standards Notice from NYSE - Marketscreener.com
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024 - Marketscreener.com
Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery - Marketscreener.com
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss - Marketscreener.com
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program - Marketscreener.com
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon - Marketscreener.com
Allurion Technologies, Inc. Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon - Marketscreener.com
Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference - Marketscreener.com
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity - Marketscreener.com
Allurion Technologies : Proxy Statement Form 8 K - Marketscreener.com
Allurion Technologies Inc. Appoints Brendan Gibbons as Its New Chief Legal Officer and Corporate Secretary - Marketscreener.com
Allurion Technologies, Inc. Announces Publication of New Data Demonstrating Continued Weight Loss at One Year on the Allurion Program - Marketscreener.com
Allurion Launches in the US with Its First AI-Native Compounded GLP-1 Program - Marketscreener.com
Allurion Technologies Inc. Announces the Appointment of Keith Johns to Its Board of Directors - Marketscreener.com
Allurion Technologies Inc. Appoints Ojas A. Buch as Chief Operating Officer - Marketscreener.com
Allurion Technologies Inc. Appoints Adrian Wild as Senior Vice President, International Commercial - Marketscreener.com
Allurion Technologies (NYSE:ALUR) Sees Large Volume IncreaseHere's Why - MarketBeat
Allurion Technologies Announces Reverse Stock SplitOn December 23, 2024, Allurion Technologies, Inc. (NYSE: ALUR) disclosed the approval of a reverse stock split during the 2024 Annual Meeting of Stockholders. The reverse stock split of the Company’s - Defense World
Allurion Technologies : Announces Reverse Stock Split Form 8 K - Marketscreener.com
Financial Review: Alphatec (NASDAQ:ATEC) versus Allurion Technologies (NYSE:ALUR) - Defense World
Allurion Technologies Stock Scheduled to Reverse Split on Friday, January 3rd (NYSE:ALUR) - Defense World
Allurion Technologies to implement reverse stock split - MSN
Allurion Technologies announces reverse stock split By Investing.com - Investing.com Nigeria
Allurion Details Reverse Stock Split - MENAFN.COM
Allurion Technologies Announces 1-for-25 Reverse Stock Split; Shares Fall Pre-Bell - Marketscreener.com
Allurion Technologies announces reverse stock split - Investing.com
Allurion Technologies, Inc. Announces Reverse Stock Split - Business Wire
Allurion Technologies shareholders approve key proposals - Investing.com
Allurion Technologies shareholders approve key proposals By Investing.com - Investing.com UK
Analyze Allurion Technologies Inc (NYSE: ALUR) Before Investing. - Stocks Register
Allurion gains NYSE compliance plan acceptance By Investing.com - Investing.com Canada
Allurion Technologies (NYSE:ALUR) vs. AVITA Medical (NASDAQ:RCEL) Head-To-Head Contrast - Defense World
ALURAllurion Technologies, Inc. Latest Stock News & Market Updates - StockTitan
Allurion Technologies Inc Stock (ALUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):